

This article was downloaded by:

On: 22 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713454007>

Cytotoxic *ent*-kaurane diterpenoids from *Isodon macrophyllus*

Ji-Xia Zhang^a; Zhi-An He^a; Zheng-Yue Chen^a; Yong-Xue Wang^a; Su-Ping Bai^a; Han-Dong Sun^b

^a Pharmaceutical Laboratory, Xinxiang Medical University, Xinxiang, Henan Province, China ^b State

Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan, China

To cite this Article Zhang, Ji-Xia , He, Zhi-An , Chen, Zheng-Yue , Wang, Yong-Xue , Bai, Su-Ping and Sun, Han-Dong(2009) 'Cytotoxic *ent*-kaurane diterpenoids from *Isodon macrophyllus*', *Journal of Asian Natural Products Research*, 11: 8, 693 – 697

To link to this Article: DOI: 10.1080/10286020802361271

URL: <http://dx.doi.org/10.1080/10286020802361271>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Cytotoxic *ent*-kaurane diterpenoids from *Isodon macrophyllus*

Ji-Xia Zhang^{a*}, Zhi-An He^a, Zheng-Yue Chen^a, Yong-Xue Wang^a, Su-Ping Bai^a and Han-Dong Sun^b

^aPharmaceutical Laboratory, Xinxiang Medical University, Xinxiang, Henan Province, China; ^bState Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan, China

(Received 18 March 2008; final version received 16 June 2008)

Two new *ent*-kaurane diterpenoids, dayecrystals D–E (**1–2**), together with nine known compounds, isojaponin A (**3**), rabdosin A (**4**), lushanrubescensin J (**5**), wikstroemioidin B (**6**), maoyecrystal C (**7**), rabdosin B (**8**), isodonal (**9**), shikokianin (**10**), and effusanin A (**11**), were isolated from the leaves of *Isodon macrophyllus*. The structures of the new compounds were elucidated using 1D and 2D NMR spectroscopy. The ¹³C-NMR spectral data of compound **4** are reported for the first time. All of the compounds were tested for their cytotoxicities against DU145 and LoVo human tumor cells. Compounds **4**, **10**, and **11** showed inhibitory effects on DU145 cells with IC₅₀ values 5.90, 4.24, and 3.16 μM, and LoVo cells with IC₅₀ values 14.20, 17.55, and 3.02 μM, respectively.

Keywords: *Isodon macrophyllus*; *ent*-kauranoids; diterpene; dayecrystals D–E; cytotoxicity

1. Introduction

Plants belonging to the genus *Isodon* are known to be a rich source of *ent*-kaurane diterpenoids, most of which have been shown to have anti-tumor and anti-inflammatory activities [1]. A series of *ent*-kaurane diterpenoids from *Isodon macrophyllus* (Migo) H. Hara have been previously reported by our research group [2–4]. The continuous research for bioactive diterpenoids from this plant led to the isolation of two new diterpenoids (**1–2**) and nine known diterpenoids (**3–11**). We now report the isolation and the structure elucidation of these diterpenoids and their biological activities against human tumor DU145 and LoVo cell lines.

2. Results and discussion

Compound **1** exhibited a molecular formula C₂₂H₃₂O₇ based on its HRESIMS at *m/z*

431.2049 [M + Na]⁺. A 6,7-*seco*-6,20-epoxy-1,7-olide-*ent*-kaurane skeleton was evident from the characteristic ¹H- and ¹³C-NMR spectra of **1** showing the presence of two tertiary methyl carbons (δ_C 33.0, 23.7), three non-oxygenated methine carbons (δ_C 53.2, 53.3, and 31.6), three non-oxygenated quaternary carbons (δ_C 57.6, 50.8, and 31.1), an oxygenated methylene carbon (δ_C 74.7), a δ-lactone carbon (δ_C 171.2), a hemiacetal carbon (δ_C 109.1), and a carbonyl carbon (δ_C 212.0). Comparison of the ¹³C chemical shifts of **1** with those of rabdosin A (**4**) [7] indicated that the difference between them was that the exomethylene in **4** was replaced by a methine at δ_C 56.4 (C-16) and a methoxymethyl group at δ_C 59.0 (OMe) and δ_C 69.2 (C-17) in **1** (Figure 1). The NOESY spectra gave correlation between the H₂-17 and the methoxy proton, which led to the assignment of the methoxy group on C-17. The upfield

*Corresponding author. Email: zjx@xxmu.edu.cn




Figure 1. The structures of compounds **1**, **2**, and **4**.

shift of the ^{13}C NMR signal for C-12 (δ_{C} 33.1 for **1**, δ_{C} 41.9 for **4**) caused by a γ -gauche shielding effect between MeO-17 and H-12 α confirmed the configuration of the methoxymethyl group as α [5]. The above conclusion was also confirmed by the NOESY correlations of H-16 β with H-13 β (see Figure 2). Therefore, the structure of compound **1** was represented as 11 α -hydroxy-6 β -methoxyl-16 α -methoxymethyl-6, 7-*seco*-6, 20-epoxy-1 α , 7-olide-*ent*-kaur-15-one.

Compound **2** was found to have a molecular formula of $\text{C}_{21}\text{H}_{28}\text{O}_7$ by the HRESIMS at m/z 415.1735 $[\text{M} + \text{Na}]^+$. The ^{13}C -NMR spectral data of **2** and **1** were closely coincident, indicating they have the same carbon skeleton. The only difference was that **2** had one oxygenated quaternary carbon (δ_{C} 75.6) and one oxygenated methylene (δ_{C} 47.8), instead of a C-16 methoxymethyl unit in **1**. Inspection of the HMBC spectra of **2** showed that the

oxygenated methylene proton signals (δ_{H} 4.46, 4.32) correlated with the quaternary carbon (δ_{C} 75.6), while the latter carbon signal showed cross-peaks with H-12 α (δ_{H} 2.91) and H-14 (δ_{H} 2.82, 2.57) (see Table 2). Thus, the epoxy group was assigned to C-16 and C-17, according to the molecular formula of **2** and its unsaturation. The β -orientation of the epoxy ring was ensured by the NOESY correlations of H-17 β with H-13 β and H-12 β (see Figure 2). Therefore, compound **2** was determined to be 11 α -hydroxy-6 β -methoxyl-6, 7-*seco*-16 β , 17: 6, 20-diepoxy-1 α , 7-olide-*ent*-kaur-15-one.

The structures of compounds **3**–**11** were characterized by comparing their m.p., IR, MS, ^1H , and ^{13}C NMR chemical shifts with those reported in literatures [6–13].

Cytotoxicity of compounds **1**–**11** against two kinds of human tumor cells (DU145 and LoVo) was tested according to the previously described method [12]. Compounds **4**, **10**, and




Figure 2. The NOESY correlations of **1** and **2**.

11 were significantly cytotoxic against the DU145 cells with IC_{50} values of 5.90, 4.24, and 3.16 μM , respectively. Compound **11** was most active against the LoVo cells with IC_{50} value of 3.02 μM . The other compounds were almost non-cytotoxic against the two cell lines ($IC_{50} > 20 \mu\text{M}$).

3. Experimental

3.1 General experimental procedures

Melting points were determined with a Kofler melting point apparatus and are uncorrected. Optical rotations were measured on a Perkin-Elmer 341 polarimeter. UV spectra were recorded on a Shimadzu UV-2550 instrument. IR spectra were taken on a Nicolet 170SX FT-IR spectrometer. ^1H , ^{13}C , and 2D NMR spectra were recorded on a Bruker AM-400 NMR spectrometer with TMS as internal standard. HRESIMS was obtained on a Waters HPLCQ-ToF HR-MS spectrometer. Silica gel (200–300 mesh) used for column chromatography and silica gel GF₂₅₄ (10–40) for TLC were from Qingdao Marine Chemicals, Qingdao, China. Fractions were monitored by TLC on silica gel and spots were visualized by heating silica gel plates sprayed with 10% H_2SO_4 in EtOH (v/v).

3.2 Plant material

The leaves of *I. macrophyllus* (Migo) C.Y.WU. et H. W. Li were collected from Tongbai Prefecture of Henan province, China, in August 2003. The plant material was identified by Prof. Zhong-wen Lin, Kunming Institute of Botany, Chinese Academy of Sciences. A voucher specimen (200308-XXMU-Lin) is deposited in the herbarium of the College of Pharmacy, Xinxiang Medical University.

3.3 Extraction and isolation

The dried and powdered leaves (10.0 kg) of *I. macrophyllus* were extracted three times with 70% Me_2CO ($3 \times 40\text{l}$) at room temperature for 3 days and filtered. The filtrate was

concentrated and partitioned with EtOAc ($4 \times 10\text{l}$). The EtOAc layer was evaporated under reduced pressure to give 360 g of residue, which was absorbed on 560 g silica gel and subjected to silica gel column ($10 \times 100\text{cm}$, 200–300 mesh, 3000 g) gradually eluted with CHCl_3 (13l), CHCl_3 – MeOH (30:1, 10:1, 9:1, 8:2, 7:3, 6:4, 0:1, each in 20l) to yield eight fractions (1–8). Fraction 1 (31 g) was chromatographed on silica gel column chromatography ($5 \times 60\text{cm}$, 200–300 mesh, 700 g) gradually eluted with $\text{PE-Me}_2\text{CO}$ (20:1, 15:1, 10:1, 5:1, each in 4000 ml) to afford compounds **7** (11 mg), **8** (16 mg), **9** (83 mg), and **10** (32 mg). Fraction 2 (104 g) was further separated on a silica gel column chromatography ($8 \times 80\text{cm}$, 200–300 mesh, 1600 g) into six fractions (2a–2f) by eluting with CHCl_3 – MeOH (1:0, 9:1, 8:2, 7:3, 6:4, 0:1, each in 10l). Fraction 2b (13 g) was subjected to silica gel column chromatography ($4 \times 50\text{cm}$, 200–300 mesh, 300 g) and eluted with CHCl_3 – MeOH (100:1, 70:1, 50:1, 25:1, 10:1, each in 2000 ml) to afford three parts. Compound **1** (54 mg) was obtained from the third part by column chromatography with CHCl_3 – Me_2CO (50:1). Compound **2** (16 mg) was acquired from the first part by column chromatography with CHCl_3 – Me_2CO (50:1) as eluent. The second part was repeatedly chromatographed by silica gel column and purified by recrystallizing in CHCl_3 – Me_2CO (10:1) to afford compound **4** (33 mg). Fraction 2d was repeatedly chromatographed over silica gel column and purified by recrystallizing in CHCl_3 – Me_2CO (10:1) to afford compound **5** (17 mg). Compounds **3** (45 mg), **6** (8 mg), and **11** (5 mg) were obtained from fraction 2c by column chromatography with CHCl_3 – MeOH (100:1) as eluent and recrystallization in MeOH .

3.3.1 Dayecrystal D (**1**)

Colorless needles (Me_2CO), $\text{C}_{22}\text{H}_{32}\text{O}_7$, m.p.: 148–150°C; $[\alpha]_{\text{D}}^{20}$: -18.0 (c 0.24, MeOH); IR (KBr) ν_{max} : 3394, 2951, 2914, 2851, 1762, 1726, 1492, 1460, 1390, 1288, 1260, 1196, 1110, 1053, 1026, 973, 922 cm^{-1} ; UV λ_{max} (MeOH): no absorption; $^1\text{H-NMR}$ ($\text{C}_5\text{D}_5\text{N}$,

400 MHz): 85.00 (1H, s, H-6 α), 4.83 (1H, dd, $J = 6.8, 10.8$ Hz, H-1 β), 4.35 (1H, m, H-11 β), 4.25 (2H, s, H₂-20), 3.69 (1H, dd, $J = 4.4, 10.4$ Hz, H-17a), 3.61 (1H, d, $J = 10.4$ Hz, H-17b), 3.32 (1H, s, H-5 β), 3.20 (3H, s, OMe), 3.15 (3H, s, OMe), 2.96 (1H, m, H-16 β), 2.76 and 1.94 (each 1H, m, H-14 a/b), 2.73 (1H, m, H-13 β), 2.60 and 1.78 (each 1H, m, H-12 a/b), 2.50 (1H, d, $J = 10.8$ Hz, H-9 α), 1.83 (2H, m, H₂-2), 1.29 (2H, m, H₂-3), 0.94 and 0.90 (each 3H, s, 2 \times Me); ¹³C-NMR (DEPT) spectral data see Table 1; HRESIMS: m/z 431.2049 [M + Na]⁺ (calcd for C₂₂H₃₂O₇Na, 431.2046) (Table 2).

3.3.2 Dayecrystal E (2)

Colorless needles (Me₂CO), C₂₁H₂₈O₇, m.p.: 270–273°C; [α]_D²⁰: –8.2 (c 0.40, MeOH); IR (KBr) ν_{\max} : 3453, 3290, 2921, 2855, 1770, 1735, 1462, 1315, 1263, 1197, 1108, 1050, 1028, 978, 919, 801 cm⁻¹; UV λ_{\max} (MeOH): no absorption; ¹H-NMR (C₅D₅N, 400 MHz): 84.99 (1H, s, H-6 α), 4.95 (1H, m, H-1 β), 4.46

Table 1. ¹³C (100 MHz) NMR spectral data of compounds **1**, **2**, and **4** in C₅D₅N (δ in ppm, J in Hz).

	1	2	4
1	77.3 d	77.1 d	77.0 d
2	24.1 t	23.6 t	24.2 t
3	37.1 t	36.6 t	37.1 t
4	31.1 s	31.3 s	31.7 s
5	53.2 d	52.9 d	53.3 d
6	109.1 d	109.2 d	109.7 d
7	171.2 s	169.7 s	171.3 s
8	57.6 s	58.3 s	57.2 s
9	53.3 d	54.4 d	53.2 d
10	50.8 s	51.0 s	51.4 s
11	64.0 d	63.1 d	64.4 d
12	33.1 t	31.4 t	41.9 t
13	31.6 d	41.2 d	35.8 d
14	35.1 t	34.2 t	33.9 t
15	212.0 s	204.0 s	201.0 s
16	56.4 d	75.6 s	151.0 s
17	69.2 t	47.8 t	118.1 s
18	33.0 q	32.5 q	33.1 q
19	23.7 q	23.3 q	23.6 q
20	74.7 t	74.2 t	74.5 t
OMe	54.7 q	54.4 q	54.8 q
OMe	59.0 q		

Table 2. HMBC correlations of compounds **1** and **2**.

No.	1	2
C-1	H-2a/b, 3a/b, 20a/b	H-3a/b, 9 α , 20a
C-2	H-1 β , 3a/b	H-1 β , 3a/b, 5 β
C-3	H-18, 19	H-18, 19
C-4	H-2a/b, 3a/b 5 β , 6 α , 18, 19	H-5 β , 6 α , 18, 19
C-5	H-1 β , 3a/b, 9 α , 18, 19, 20a/b	H-6 α , 18, 19, 20a/b
C-6	H-3a/b, 5 β , OMe, 20a/b	H-5 β , OMe, 20a/b
C-7	H-9 α , 14b	
C-8	H-9 α , 14b	H-9 α , 13 β
C-9	H-1 β , 5 β , 12b, 14a/b, 20a/b	H-1 β , 5 β , 12b, 14a
C-10	H-2a/b, 5 β , 6 α , 9 α , 20a/b	H-1 β , 6 α , 9 α , 20a/b
C-11	H-9 α , 12a, 13 β , 20a/b	H-6 α , 9 α , 12a/b, 13 β
C-12	H-9 α , 14b	H-9 α , 13 β , 14b
C-13	H-12a, 14a, 16 β , 17a/b	H-12a/b, 14a, 17b
C-14	H-12a, 16 β	H-12a
C-15	H-9 α , 12b, 14a, 16 β , 17a/b	H-9 α , 13 β , 14a/b
C-16	H-12a, 13 β , 14a, 17a/b	H-12a, 13 β , 14a/b, 17a/b
C-17	H-16 β , OMe	
C-18	H-3a/b, 5 β , 19	H-5 β , 19
C-19	H-3a/b, 5 β , 18	H-5 β , 18
C-20	H-1 β , 5 β , 6 α , 9 α	H-1 β , 5 β , 6 α , 9 α
OMe	H-6 α	H-6 α
OMe	H-17a/b	

and 4.32 (each 1H, d, $J = 13.2$ Hz, H-17a/b), 4.41 (1H, m, H-11 β), 4.26 and 4.17 (each 1H, ABd, $J = 10.0$ Hz, H₂-20), 3.24 (1H, s, H-5 β), 3.06 (3H, s, OMe), 2.91 and 1.98 (each 1H, m, H-12 a/b), 2.86 (1H, m, H-13 β), 2.82 and 2.57 (each 1H, m, H-14 a/b), 2.62 (1H, d, $J = 10.4$ Hz, H-9 α), 1.85 (2H, m, H₂-2), 1.35 (2H, m, H₂-3), 0.95 and 0.91 (each 3H, s, 2 \times Me); ¹³C-NMR (DEPT) spectral data, see Table 1; HRESIMS: m/z 415.1735 [M + Na]⁺ (calcd for C₂₁H₂₈O₇Na, 415.1732).

3.4 Tests of cytotoxicity against human tumor DU145 and LoVo cells

Previously described bioassay methods were adopted [14].

References

- [1] H.D. Sun, Y.L. Xu, and B. Jiang, *Diterpenoids from Isodon Species*, (Science Press, Beijing, 2001), p. 2.
- [2] J.X. Zhang, Z.Y. Chen, Y.X. Wang, and P.Y. Qiu, *J. Xinxiang Med. Coll.* **1**, 16 (2006).
- [3] J.X. Zhang, Z.Y. Chen, Y.X. Wang, P.Y. Qiu, S.X. Huang, and H.D. Sun, *J. Chem. Res.* **7**, 420 (2006).
- [4] J.X. Zhang, Z.Y. Chen, Y.X. Wang, and P.Y. Qiu, *J. Chin. Med. Mater.* **7**, 794 (2007).
- [5] B.L. Li and X.H. Tian, *Phytochemistry* **58**, 543 (2001).
- [6] L.B. Yang, S.X. Huang, L.M. Li, Y. Zhao, C. Lei, W.L. Xiao, J.X. Pu, Q.B. Han, and H.D. Sun, *Helv. Chim. Acta.* **90**, 2375 (2007).
- [7] J.C. Li, C.J. Liu, X.Z. An, M.T. Wang, T.Z. Zhao, S.Z. Yu, G.S. Zhao, and R.F. Chen, *Acta Pharm. Sin.* **9**, 44 (1982).
- [8] Q.B. Han, Y. Lu, L. Wu, Z.D. He, C.F. Qiao, H.X. Xu, Q.T. Zheng, and H.D. Sun, *Tetrahedron Lett.* **32**, 5373 (2005).
- [9] S.H. Wu, H.J. Zhang, Y.P. Cheng, Z.W. Lin, and H.D. Sun, *Phytochemistry* **4**, 1099 (1993).
- [10] Q.B. Han, J.X. Zhang, Y.H. Shen, and H.D. Sun, *Chin. J. Nat. Med.* **1**, 16 (2003).
- [11] Q.Z. Zhao, J.H. Chao, H.Q. Wang, and H.D. Sun, *Chin. Herb. Med.* **2**, 49 (1984).
- [12] F.M. Xu, H.P. Hu, and Z.Q. Wang, *Chin. J. Chin. Mat. Med.* **11**, 678 (1996).
- [13] T. Fujita, Y. Takeda, T. Shingu, and A. Ueno, *Chem. Lett.* **12**, 1635 (1980).
- [14] S.P. Bai, Q.Y. Wei, X.L. Jin, and L. Yang, *Planta Med.* **71**, 1 (2004).